Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), LAVA Therapeutics (LVTX) and Design Therapeutics (DSGN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Illumina (ILMNResearch Report), LAVA Therapeutics (LVTXResearch Report) and Design Therapeutics (DSGNResearch Report).

Illumina (ILMN)

In a report issued on September 26, Puneet Souda from SVB Securities maintained a Hold rating on Illumina, with a price target of $220.00. The company’s shares closed last Tuesday at $186.84, close to its 52-week low of $173.45.

According to TipRanks.com, Souda has 0 stars on 0-5 stars ranking scale with an average return of -14.4% and a 29.7% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

Illumina has an analyst consensus of Hold, with a price target consensus of $250.38.

See today’s best-performing stocks on TipRanks >>

LAVA Therapeutics (LVTX)

SVB Securities analyst Daina Graybosch reiterated a Buy rating on LAVA Therapeutics on September 26 and set a price target of $28.00. The company’s shares closed last Tuesday at $4.53.

According to TipRanks.com, Graybosch is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -22.0% and a 25.9% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Bolt Biotherapeutics, Century Therapeutics, and Nektar Therapeutics.

Currently, the analyst consensus on LAVA Therapeutics is a Strong Buy with an average price target of $17.33, representing a 257.3% upside. In a report issued on September 15, JMP Securities also initiated coverage with a Buy rating on the stock with a $6.00 price target.

Design Therapeutics (DSGN)

SVB Securities analyst Joseph Schwartz reiterated a Buy rating on Design Therapeutics on September 25 and set a price target of $30.00. The company’s shares closed last Tuesday at $15.83.

According to TipRanks.com, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.6% and a 30.7% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Crinetics Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Design Therapeutics with a $28.67 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ILMN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos